About DIA


For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in health care product development and life cycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation.


DIA Global Chief Executive Barbara Lopez Kunz and Dr. Sandra Milligan, DIA President and Chairman of the Board, reflect on how DIA breaks through the barriers between academia, industry, regulatory and government agencies, and patient groups, to fulfill the noble promise of our respective professions: To deliver safe and effective health care products to patients all around the world.

DIA Mission

DIA fosters innovation to improve health and well-being worldwide by:

  • Providing invaluable forums to exchange vital information and discuss current issues related to health care products, technologies, and services;
  • Delivering customized learning experiences;
  • Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and
  • Offering a multidisciplinary neutral environment, respected globally for integrity and relevancy.

DIA Vision

DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate health care product development.

Nominations for DIA Board of Directors Now Closed

October 21, 2016 – November 21, 2016

The DIA Board of Directors sets the strategic direction and governance for the association.  Elected, executive-level leaders will aid in our growth and impact against DIA’s top priorities. Nominations are for the July 2017-June 2020 Term.

Nominees will be notified of final selection in April 2017. 

Our Leadership

A History of Accomplishment

DIA, a non-profit association, was founded in 1964 as a neutral global membership association dedicated to improving communication and collaboration in drug development. That goal remains the same today.

The organization was born out of a true need. DIA’s founding was closely tied to the 1962 passage of sweeping legislation passed in the United States in response to the finding that use of thalidomide to treat morning sickness caused birth defects. Although the problem was global, there was no organization at the time that could foster cooperative efforts across the entire world. Seeing the need, a group of 30 pharmaceutical professionals, medical writers, and academics created DIA as a fully independent, unbiased, non-profit association.

The neutral posture of DIA encourages active participation. Because membership spans all aspects of health care product development and life cycle management, members are free to collaborate fully as they explore fresh ideas and think outside of their traditional fields. Today, DIA is a worldwide organization in more than 80 countries with regional offices covering the Americas, Europe, Asia, the Middle East, and Africa.